[
    [
        {
            "time": "2023-10-05",
            "original_text": "House Panel Investigating Drug Prices To Subpoena AbbVie",
            "features": {
                "keywords": [
                    "House Panel",
                    "Drug Prices",
                    "Subpoena",
                    "AbbVie"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "House Panel Investigating Drug Prices To Subpoena AbbVie",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "AbbVie 'Surprised, Disappointed' by House Panel Subpoena Plan",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Surprised",
                    "Disappointed",
                    "House Panel",
                    "Subpoena"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie 'Surprised, Disappointed' by House Panel Subpoena Plan",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "U.S. House Oversight Committee to subpoena AbbVie in drug-pricing probe",
            "features": {
                "keywords": [
                    "U.S. House Oversight Committee",
                    "subpoena",
                    "AbbVie",
                    "drug-pricing",
                    "probe"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "U.S. House Oversight Committee to subpoena AbbVie in drug-pricing probe",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Forget Johnson & Johnson, AbbVie Is a Better Dividend Stock",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "AbbVie",
                    "Better Dividend Stock"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Forget Johnson & Johnson, AbbVie Is a Better Dividend Stock",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]